News and Updates

Breakthrough T1D sat down with Mason Miller to learn more about his journey with type 1 diabetes and the impact it has on him as an athlete.

What’s happening? Continuous ketone monitoring (CKM) is on its way. A new paper in The Lancet Diabetes & Endocrinology, titled “International expert recommendations on the application and utility of continuous ketone monitoring for people with diabetes,” was published by Breakthrough T1D and expert collaborators, spearheaded by our Chief Medical Officer, International, Thomas Danne, M.D., Ph.D. […]

Skin reactions from adhesives on insulin pumps and CGMs are common. Learn why they occur and how to reduce irritation.

What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]

Analysis compiled by Avalere Health and supported by Breakthrough T1D (formerly JDRF) finds that research funded by the Special Diabetes Program (SDP) has yielded more than $50 billion in federal healthcare savings.  Created by Congress in 1997 and administered by the National Institutes of Health (NIH), the SDP provides federal funding to support research to prevent, treat, and […]

As Breakthrough T1D’s largest corporate partner, Marshalls has raised more than $47 million to-date to improve and change life with type 1 diabetes.

For students with type 1 diabetes who use technology to manage the condition, school cell phone bans can present challenges.

Continuous glucose monitors have been transformative for daily type 1 diabetes management. Can they benefit people without diabetes?

Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]

Breakthrough T1D recently published two peer-reviewed journal articles. One detailed burdensome unmet needs in the T1D community and identified key steps we can take to meet these needs. The other used real-world data to better understand American T1D demographics and predict changes in the next decade.